Volume 34, Issue 4, December 2023

Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2023;34(4):418-26
Disease Profile and Achievement of Therapeutic Goals in a Modern, Nationwide Cohort of 923 Patients with Psoriatic Arthritis
Authors Information
  1. Joint Academic Rheumatology Program, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
  2. First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
  3. Department of Rheumatology, KAT Hospital, Athens, Greece
  4. Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece
  5. Joint Academic Rheumatology Program, 4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
  6. 4th Department of Medicine, Aristotle University, Thessaloniki, Greece
  7. Department of Rheumatology and Clinical Immunology, University of Thessaly, Larissa, Greece
  8. Joint Academic Rheumatology Program, Clinical Immunology, Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens Medical School, General Hospital of Athens “Hippokration”, Athens, Greece
  9. Rheumatology Clinic, Naval Hospital of Athens, Athens, Greece
  10. Rheumatology Unit, Sismanoglio Hospital, Athens, Greece
  11. Rheumatology Department, General Hospital Elefsinas Thriaseio, Athens, Greece
  12. Department of Rheumatology, "Asklepieion" General Hospital, Athens, Greece
  13. Department of Rheumatology, Evaggelismos Athens General Hospital, Athens, Greece
  14. Department of Rheumatology, Patras University Hospital, University of Patras Medical School, Patras, Greece
  15. Private practice, Athens, Greece

Background: Psoriatic arthritis (PsA) is a heterogenous chronic inflammatory disease affecting skin, joints, entheses, and spine with various extra-musculoskeletal manifestations and comorbidities. The reported patient, disease and treatment characteristics in the modern therapeutic era are limited. Methods: In this cross-sectional, multi-centre, nationwide study, we recorded the demographic, clinical, and therapeutic characteristics as well as the comorbidities of patients with PsA seen for 1 year (1/1/2022-31/12/2022). Results: 923 patients (55% females) with a median (IQR) age of 57 (48-65) years and a mean disease duration of 9.5 years were enrolled. Family history of psoriasis and PsA was noted in 28.3% and 6.3%, respectively. Most patients had limited psoriasis (BSAConclusion: In this large, real life, modern cohort of patients with PsA with frequent comorbidities who were treated mainly with biologics, almost half achieved minimal disease activity. These results show the value of existing therapeutic approaches while at the same time highlight the existing unmet needs.


Cite this article as: Fragoulis GE, Papagoras C, Gazi S, Mole E, Krikelis M, Voulgari PVV, Kaltsonoudis E, Koletsos N, Katsimpri P, Boumpas D, Katsifis D, Kougkas N, Dimitroulas T, Sfikakis PP, Tektonidou MG, Gialouri C, Bogdanos DP, Simopoulou T, Koutsianas C, Mavrea E, Katsifis G, Kottas K, Konsta M, Tziafalia M, Kataxaki E, Kalavri E, Klavdianou K, Grika EP, Sfontouris C, Daoussis D, Iliopoulos G, Bournazos I, Karokis D, Georganas K, Patrikos D, Vassilopoulos D. Disease Profile and Achievement of Therapeutic Goals in a Modern, Nationwide Cohort of 923 Patients with Psoriatic Arthritis. Mediterr J Rheumatol 2023;34(4):418-26

Article Submitted: 10 Dec 2023; Article Accepted: 11 Dec 2023; Available Online: 30 Dec 2023

This work is licensed under a Creative Commons Attribution 4.0 International License.

©2023 The Author(s).